IPSEN (OTCMKTS:IPSEY – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $33.57 and traded as high as $34.93. IPSEN shares last traded at $34.93, with a volume of 1,301 shares changing hands.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on IPSEY shares. BNP Paribas cut shares of IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research report on Monday, November 3rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, IPSEN presently has an average rating of “Hold”.
Get Our Latest Stock Report on IPSEN
IPSEN Stock Down 0.0%
About IPSEN
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Read More
- Five stocks we like better than IPSEN
- Do not delete, read immediately
- The Crash Has Already Started (Most Just Don’t See It Yet)
- ALERT: Drop these 5 stocks before January 2026!
- [No Brainer Gold Play]: “Show me a better investment.”
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
